Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Jönsson, Linus [VerfasserIn]   i
 Wimo, Anders [VerfasserIn]   i
 Handels, Ron [VerfasserIn]   i
 Johansson, Gunilla [VerfasserIn]   i
 Boada, Mercè [VerfasserIn]   i
 Engelborghs, Sebastiaan [VerfasserIn]   i
 Frölich, Lutz [VerfasserIn]   i
 Jessen, Frank [VerfasserIn]   i
 Kehoe, Patrick Gavin [VerfasserIn]   i
 Kramberger, Milica [VerfasserIn]   i
 de Mendonςa, Alexandre [VerfasserIn]   i
 Ousset, Pierre Jean [VerfasserIn]   i
 Scarmeas, Nikolaos [VerfasserIn]   i
 Visser, Pieter Jelle [VerfasserIn]   i
 Waldemar, Gunhild [VerfasserIn]   i
 Winblad, Bengt [VerfasserIn]   i
Titel:The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease
Titelzusatz:an EADC-EC viewpoint
Verf.angabe:Linus Jönsson, Anders Wimo, Ron Handels, Gunilla Johansson, Mercè Boada, Sebastiaan Engelborghs, Lutz Frölich, Frank Jessen, Patrick Gavin Kehoe, Milica Kramberger, Alexandre de Mendonςa, Pierre Jean Ousset, Nikolaos Scarmeas, Pieter Jelle Visser, Gunhild Waldemar, and Bengt Winblad
E-Jahr:2023
Jahr:June 2023
Umfang:7 S.
Illustrationen:Illustrationen
Fussnoten:Online verfügbar: 22. Mai 2023, Artikelversion: 22. Mai 2023 ; Gesehen am 07.08.2024
Titel Quelle:Enthalten in: The lancet. Regional health
Ausgabe Quelle:Europe
Ort Quelle:[Amsterdam] : Elsevier, 2021
Jahr Quelle:2023
Band/Heft Quelle:29(2023), Artikel-ID 100657, Seite 1-7
ISSN Quelle:2666-7762
Abstract:Lecanemab, an anti-amyloid antibody with effects on biomarker and clinical endpoints in early Alzheimer's Disease (AD), was granted accelerated approval by the FDA in 2023 and regulatory review in Europe is ongoing. We estimate the population potentially eligible for treatment with lecanemab in the 27 EU countries to 5.4 million individuals. Treatment costs would exceed 133 billion EUR per year if the drug is priced similarly as in the United States, amounting to over half of the total pharmaceutical expenditures in the EU. This pricing would be unsustainable; the ability to pay for high-priced therapies varies substantially across countries. Pricing similarly to what has been announced for the United States may place the drug out of reach for patients in some European countries. Disparities in access to novel amyloid-targeting agents may further deepen the inequalities across Europe in health outcomes. As representatives of the European Alzheimer's Disease Consortium Executive Committee, we call for pricing policies that allow eligible patients across Europe to access important innovations, but also continued investments in research and development. Infrastructure to follow up the usage of new therapies in routine care and new payment models may be needed to address affordability and inequalities in patient access.
DOI:doi:10.1016/j.lanepe.2023.100657
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.1016/j.lanepe.2023.100657
 kostenfrei: Volltext: https://www.sciencedirect.com/science/article/pii/S2666776223000765
 DOI: https://doi.org/10.1016/j.lanepe.2023.100657
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Antibodies against amyloid b-peptide
 Health economics
 Lecanemab
 Mild AD
 Passive immunotherapy
 Pricing
 Prodromal AD
K10plus-PPN:1898062412
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69241308   QR-Code
zum Seitenanfang